71088 Holzgerlingen, de
+49 (40) 881659-64
Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017
Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced its participation in several industry conferences in the first quarter of 2017. The respective presentations will be made available on the company's website.
J.P. Morgan 35th Annual Healthcare Conference 2017, January 9-13, 2017 - San Francisco, CA, USA: one-on-one meetings.
Society of Critical Care Medicine's (SCCM) 46th Critical Care Congress, January 21-25, 2017 - Honolulu, Hawaii, USA: exhibition booth: 924.
Invest Securities BioMed Event, January 26, 2017 - Paris, France: company presentation and one-on-one meetings.
DeGroof Petercam Life Sciences Investor Day, January 31, 2017 - Brussels, Belgium: one-on-one meetings.
3rd Annual Medtech & Money Healthcare Conference, February 7-8, 2017 - London, United Kingdom: company presentation and one-on-one meetings.
BIO CEO & Investor Conference, February 13-14, 2017 - New York, NY, USA: company presentation and one-on-one meetings.
RBC Healthcare Conference 2017, February 22-23, 2017 - New York, NY, USA: company presentation and one-on-one meetings.
Microbiology and Infection 2017; 5th Joint Conference of the DGHM & VAAM
VAAM Annual Meeting 2017; 69th Annual Meeting of the DGHM, March 5-8, 2017 - Wuerzburg, Germany.
Sachs 10th European Life Science CEO Forum & Exhibition, March 6-7, 2017 - Basel, Switzerland: company presentation and one-on-one meetings.
BioCapital Europe 2017, March 15, 2017 - Amsterdam, The Netherlands: company presentation and one-on-one meetings.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.